MK6186 in HIV-1 Infected Patients (MK-6186-007 AM2)

NCT01152255 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV-1 Infection

Interventions

DRUG: MK6186
DRUG: Comparator: Placebo

Sponsor

Merck Sharp & Dohme LLC